Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Randomized, Double-blind, Positive Parallel Control Study of Compound Ciwujia Granules in the Treatment of Chronic Fatigue Syndrome (Spleen-kidney Deficiency Syndrome, Heart-spleen Deficiency Syndrome)

NCT06245642 is registered in ClinicalTrials.gov with Heilongjiang Quanle Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT06245642
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06245642 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Randomized, Double-blind, Positive Parallel Control Study of Compound Ciwujia Granules in the Treatment of Chronic Fatigue Syndrome (Spleen-kidney Deficiency Syndrome, Heart-spleen Deficiency Syndrome)
Lead sponsor
Heilongjiang Quanle Pharmaceutical Co., Ltd.
Phase
Phase 4
Overall status
Completed
Start date
March 19, 2024
Completion date
January 16, 2025
Enrollment
235 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic fatigue syndrome